Life Sciences Focus Bay City Capital LLC is a life sciences investment firm with a global diversified strategy spanning seed to public companies, indicating ongoing need for deal Sourcers, co-investors, and counterparties across biotech, pharma, and biotech-enabled services.

Experienced Leadership The firm features long-tenured partners and a substantial support team of 20 investment professionals plus advisers, suggesting opportunities for high-level partnerships, syndication, and strategic collaborations with senior decision makers.

Recent Investments Past and recent financings include a $45M Series C for NextWave Pharmaceuticals and a $20M Series A for Altheos, signaling active deal flow in early to growth-stage biopharma and potential openings for co-investments or deal co-lead opportunities.

Network and Influence With a broad professional network and scientific advisory board, the firm can influence portfolio strategy and leverage relationships to accelerate due diligence, clinical development discussions, or partnership opportunities for related life sciences ventures.

Financial Scale Reported revenue range of $50M–$100M positions Bay City Capital as a mid-to-large family of funds potential client for LP relationships, fundraising collaborations, or advisory services for growing investment programs and fund operations.